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Background: Quantitation of β-cell function is critical in better understanding of the dynamic interactions of insulin
secretion, clearance and action at different phases in the progression of diabetes. The present study aimed to
quantify β-cell secretory function independently of insulin sensitivity in the context of differential metabolic
clearance rates of insulin (MCRI) in nonhuman primates (NHPs).
Methods: Insulin secretion rate (ISR) was derived from deconvolution of serial C-peptide concentrations measured
during a 5 stage graded glucose infusion (GGI) in 12 nondiabetic (N), 8 prediabetic or dysmetabolic (DYS) and 4
overtly diabetic (DM) cynomolgus monkeys. The characterization of the monkeys was based on the fasting glucose
and insulin concentrations, glucose clearance rate measured by intravenous glucose tolerance test, and insulin
resistance indices measured in separate experiments. The molar ratio of C-peptide/insulin (C/I) was used as a
surrogate index of hepatic MCRI.
Results: Compared to the N monkeys, the DYS with normal glycemia and hyperinsulinemia had significantly higher
basal and GGI-induced elevation of insulin and C-peptide concentrations and lower C/I, however, each unit of
glucose-stimulated ISR increment was not significantly different from that in the N monkeys. In contrast, the DM
monkeys with β-cell failure and hyperglycemia had a depressed GGI-stimulated ISR response and elevated C/I.
Conclusions: The present data demonstrated that in addition to β-cell hypersecretion of insulin, reduced hepatic
MCRI may also contribute to the development of hyperinsulinemia in the DYS monkeys. On the other hand,
hyperinsulinemia may cause the saturation of hepatic insulin extraction capacity, which in turn reduced MCRI in the
DYS monkeys. The differential contribution of ISR and MCRI in causing hyperinsulinemia provides a new insight into
the trajectory of β-cell dysfunction in the development of diabetes. The present study was the first to use the GGI
and C-peptide deconvolution method to quantify the β-cell function in NHPs.
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Loss of glucose-stimulated insulin secretion from pan-
creatic islet β-cells is one of the fundamental defects in
the pathogenesis of type 2 diabetes (T2D) and portends
overt diabetes in humans and in nonhuman primates
(NHPs). Understanding of the mechanisms leading to β-
cell dysfunction is crucial for discovery and development
of novel therapies to prevent and treat diabetes. Historic-
ally, rodents have served as the mainstay of in vivo pre-
clinical models for studying normal and abnormal β-cell
function. However, spontaneous obesity, dysmetabolism
(metabolic syndrome) and diabetes are uncommon in ro-
dents and their natural history and pathogenesis is incon-
sistent with clinical observations in humans. Notably,
multiple studies have demonstrated that many of the
molecular and histologic characteristics of dysfunctional
rodent β-cells deviate from humans, while those from
NHPs are highly similar to humans in both islet architec-
ture and β-cell function. For example, amyloid deposits
which are derived from islet-associated polypeptide (IAPP)
have been frequently observed in the islets in T2D
humans [1] and NHPs [2], but are not observed in ro-
dents. Islet studies in NHPs have uncovered considerable
overlap with findings in humans. The natural history
of T2D along with changes in β-cell function has been
best described in Macaca mulatta. The NHP models
have been characterized for their use in quantifying β-
cell function, and are indispensable preclinical transla-
tional models for investigating the pathogenesis of
T2D and for testing or profiling novel anti-diabetic
agents.
About 50% of newly secreted insulin molecules are
extracted by the liver in the first pass and the extent of
hepatic insulin clearance varies by disease state and in-
sulin load [3]. In contrast, the C-peptide, co-secreted
with insulin from the β-cell on an equimolar basis, is
not significantly cleared by the liver [4,5]. In vivo assess-
ment of dynamic β-cell insulin release is most robustly
accomplished in blood samples taken directly from the
hepatic portal vein [6], an approach rarely practical in
humans, although applied sometimes in NHP studies,
because portal vein catheterization requires highly inva-
sive surgery that is not readily available in most research
settings. Fortunately, the problem can be addressed by
exploiting the co-secretion and differing clearance prop-
erties of insulin and C-peptide [7]. Hence, by mathemat-
ically modeling (with deconvolution) serially measured
circulating C-peptide and insulin concentrations under
conditions of β-cell stimulation, a surrogate of pre-hepatic
insulin secretion rate (ISR) can be derived [8]. This
deconvolution approach represents the most useful
noninvasive method of quantifying pre-hepatic insulin
secretion and has been used in clinical research [9],
but not yet been established, validated and used in anNHP species over a range of different β-cell function
conditions, including normal, prediabetes with disturbed
metabolism, and overt T2D, to quantify alterations in
insulin secretion.
Glucose-stimulated insulin release can be produced by
a single glucose injection, such as during an intravenous
glucose tolerance test (ivGTT) [10,11], or by a fixed dose
of glucose infusion [12,13]. However, these techniques
do not allow construction of a dose–response curve be-
tween glucose and ISR at various glucose concentrations.
The insulin secretory response to a more slowly and
physiologically increasing glucose stimulus is used here
to uncover novel features of β-cell function [14]. The
graded glucose infusion (GGI) has been shown in humans
to dose-dependently stimulate the β-cell release of insulin,
thus, being considered a method to quantify the β-cell in-
sulin secretory function [15,16]. Therefore, the present
study aimed to use the GGI method to quantify β-cell
function in response to gradually increaseing blood glu-
cose stimulation, and thus, to investigate the relative
contribution of insulin secretion and hepatic insulin
clearance in causing hyperinsulinemia in NHPs under
different metabolic states. Specifically we have shown
that the ISR was increased during fasting conditions in
dysmetabolic monkeys, but ISR was not different from
normal monkeys in response to glucose stimulation
during a GGI, while hepatic insulin extraction differed
significantly between the two groups. A major reduc-
tion in ISR was observed in the overt T2D monkeys.
The present study used the GGI method to quantify
the insulin secretory capacity in NHPs ranging from
normal to overtly diabetic, and identified major defects
in the ISR in the diabetic group and reduced insulin
extraction in the prediabetic/dysmetabolic group rela-
tive to normals.Methods
Twenty four cynomolgus macaques (Macaca fascicularis)
of both genders were individually housed at Crown Bio-
science Inc., Taicang, China in species appropriate cages
in a temperature-controlled room maintained at 20 ± 3°C
on a 12-hour light–dark cycle. They were fed normal pri-
mate chow containing 19% protein, 5% fat and 3.6% fiber
(Shanghai Shilin Biotechnology Inc., Shanghai, China) twice
daily and had free access to tap water. All of the experimen-
tal procedures were approved by the Institutional Animal
Care and Use Committee (IACUC) and were performed
in accordance with the Guide for the Care and Use of La-
boratory Animals (ILAR, National Academies Press, USA
2011). All experimental procedures were carried out
under light ketamine anesthesia initiated with 10 mg/kg
intramuscularly and supplemented to maintain sedation
during each experiment.
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In the absence of well-defined criteria to classify diabetes
and glucose intolerance in NHPs, we used both fasting
glucose and insulin as well as the glucose clearance rates
obtained from ivGTTs performed before the GGI experi-
ments to evaluate the metabolic stages of the monkeys
according to an established protocol [17,18]. The glu-
cose solution (50% dextrose, 0.25 g/kg) was adminis-
tered intravenously in a single bolus over a 30 second
period. Venous blood samples were obtained immedi-
ately before and at 3, 5, 10, 15, 20 and 30 min after glu-
cose administration. Glucose disappearance or
clearance rate (Kglucose) was expressed as the rate of
glucose being removed from the circulation with a one
compartment kinetic model calculated by the slope of a
linear trend best matching the natural logarithm of the
blood glucose concentrations at each time point, by fit-
ting a straight line using the least squares method with
Microsoft Excel formula: LINEST (LN (blood glucose
concentrations at each time point), 3, 5, 7, 10, 15, 20, 30
min).
The monkey colony was objectively divided into 3 dis-
tinct groups based on below criteria: metabolically normal
(N), prediabetic or dysmetabolic (DYS) and overly diabetic
(DM) with fasting glucose < 60, 60–100 and > 100 mg/dL,
and/or Kglucose > 2, 2–1.5 and < 1.5 g/min, respectively.
The quantitative insulin sensitivity check index (QUICKI)
to estimate insulin sensitivity was calculated as 1/[log
(fasting blood glucose concentration, mM) + log (fasting
serum insulin concentration, mIU/L)] [19-21]. Homeo-
static model assessment of insulin resistance (HOMA-IR)
was obtained by the fasting glucose-insulin product:
fasting blood glucose concentration (mM) x fasting
serum insulin concentration (mIU/L) / 22.5 [19,21].
All animals were weight stable prior to study initiation.
The monkeys that were classified as DM were recently
diagnosed early diabetic, not yet receiving insulin ther-
apy, and were weight stable and negative for urinary ke-
tones. Preliminary analyses using multiple regression
analysis indicated that sex did not significantly contrib-
ute to variation in any of the GGI and ivGTT outcome
variables and was subsequently not further considered in
comparisons between the groups [19,21].
Graded glucose infusion (GGI)
Experimental procedures
Under ketamine anesthesia as described above, intraven-
ous catheters were placed in the cephalic and saphenous
veins. Glucose (20% dextrose) was continuously infused
into the saphenous vein over five 40-min stages starting at
2 mg/kg/min and doubling at each successive stage up to
32 mg/kg/min. Blood was sampled at baseline (−10 and −3
min before the start of glucose infusion) and serially there-
after every 20 min for 200 min. Samples were placed onice, centrifuged within 30 min of collection and serum
obtained for biochemical assays.
Insulin secretion rate (ISR): Peripheral C-peptide levels
can be used to estimate pre-hepatic insulin secretion.
Under non-steady state conditions, however, C-peptide
kinetics are non-linear and subject to deconvolution.
Thus, C-peptide secretion, thereby pre-hepatic insulin
secretion patterns can be reassembled with the Regular-
ization Method by deconvolution of peripheral C-peptide
kinetics, using a two-compartment model implemented in
the software program ISEC [8]. This program was devel-
oped to estimate insulin secretion and standard parame-
ters for C-peptide clearance based on age, sex, weight,
length (height), and metabolic status in humans.
Hepatic metabolic clearance rate of insulin (MCRI):
Insulin and C-peptide are co-secreted from the β-cell on
an equimolar basis [4,5]. Both in vivo and in vitro re-
ports have demonstrated a large capacity of the liver to
extract insulin from the portal blood [3-5], but little or
no C-peptide removal occurs across the liver [22]. Thus,
a surrogate hepatic insulin extraction or clearance rate
can be assessed noninvasively from the C-peptide/insulin
molar ratio (C/I) measured in the peripheral blood [6].
Analyses
Blood glucose concentration was measured onsite during
the experiment with a glucometer (Accu-Chek® Performa).
The same blood samples were taken for measurement
of serum glucose concentrations by the glucose oxidase
method after the experiment. The glucose concentra-
tion values obtained by the two different methods from
blood or serum were highly correlated (r=0.99, p<0.001).
Thus, the blood glucose concentrations were used for
the data analysis in this manuscript. Serum insulin and
C-peptide levels were determined with an electrochemi-
luminescence immunoassay by a clinical instrument (Roche,
Cobas 601).
Data and statistical analyses
Data are presented as mean and standard error of the
mean. The time course (glucose infusion rate) - response
(blood glucose, insulin, C-peptide, C/I and ISR) curves were
constructed. Comparison of the parameters at each time
point after glucose infusion with the baseline value at time
0 min before glucose infusion was carried out by paired t
test. Serial data over the time course were integrated into
area under the curve (AUC) by the standard trapezoid
method as the average response over the entire GGI period.
The β-cell insulin secretory function in response to graded
glucose stimulation was analyzed by construction of the
logarithmic blood glucose concentration-response curves
for insulin, C-peptide, C/I and ISR, respectively to
quantify each unit of blood glucose change-induced
unit of change in the above parameters. The correlation
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Excel: CORREL (series of the measured parameters, LN
(series of blood glucose concentration)). The sensitivity of
glucose-stimulated insulin release was then quantified by
the slopes of the logarithmic blood glucose concentration-
response curves by best fitting a straight line on these
parameters against the natural logarithm of blood glucose
concentrations. The least squares method was used with
a formula in Microsoft Excel: LINEST (the measured
parameters against LN (each blood glucose concentra-
tion)). Group means were compared using ANOVA with
Fisher LSD pairwise post hoc comparisons. Statistical sig-
nificance was set at p<0.05. The data were analyzed using
the XLSTAT 2012 (Addinsoft Inc.) in MS Excel 2010
(Microsoft Inc.).
Results
Basal characteristics at fasting condition
Using the overnight fasting glucose and insulin, as well
as the Kglucose value obtained from the ivGTT to separ-
ate the metabolic states of the NHP colony, the fasting
serum glucose concentration was significantly higher in
the DSY, and, by definition, the highest in the DM
group. The Kglucose was significantly lower in the DYS,
and the lowest in the DM group, compared to the N
group (Table 1). The insulin sensitivity index QUICKI
was significantly lower in both the DYS and DM groups
compared to the N group, while the insulin resistance
index HOMA-IR was greater in the DYS and DM groups
relative to the N group. There were no differences in
either QUICK or HOMA-IR between the DYS and DM
groups. The DM and DYS NHPs were significantly older
than the N group, however, the body weights were not sig-
nificantly different among the groups. Since there were
proportionally more male monkeys in the N group, this
sex difference unequally contributed to the average body
weight; thus the DM and DYS were obese relative to the
N monkeys. Using the baseline value before the GGI
(Figure 1, left), the fasting blood glucose concentrations
were slightly, but significantly higher in the DYS and
the highest in the DM compared to the N group, how-
ever, the fasting insulin and C-peptide, as well as ISR,Table 1 Descriptive characteristics (mean ± standard error)
Normal (N)
Objects (Male/Female) 12 (11/1)
Age (years) 9.7 ±1.1
Body Weight (kg) 8.7 ± 0.8
Fasting Serum Glucose (mg/dL) 43.1 ± 1.8
Kglucose (g/L/min) 2.5 ± 0.2
QUICKI (1/mM+mIU/L) 0.55 ± 0.02
HOMA-IR (mM x mIU/L) 3.6 ± 0.6
* or #: significantly different from N or DYS group, respectively, p<0.05, by ANOVAwere significantly higher in the DYS than in either the
N or the DM groups. The basal C/I molar ratio was sig-
nificantly lower in the DYS, and tended to be higher but
was not statistically significantly elevated in the DM
(probably due to the great variability) compared to the
N group.
GGI-stimulated insulin secretion
The GGI procedure resulted in a progressive rise in
blood glucose concentrations in all groups (Figure 1,
middle), however, the overall glucose responses shown
as AUCs were significantly greater in the DYS and the
greatest in the DM compared to the N monkeys (Figure 1,
right). The gradual elevation in blood glucose concentra-
tions increased the ISR, thereby increasing the serum con-
centrations of insulin and C-peptide to a greater degree
in the DYS than N NHPs, but the changes were very
minimal in the DM group. The differences were more
dramatic in the late phase of the GGI time course curves
(Figure 1, middle), as well as in the integrated AUCs
representing average change during the entire GGI period
(Figure 1, right). There was a gradual decline in the C/I
in all 3 groups, however, the change was minimal in the
DYS group. Thus, the C/I time course curves gradually
merged between the DYS and N groups with no differ-
ence in AUC integrated over 200 min, although the ratio
remained significantly higher in the DM group. At the
lowest glucose infusion rate (2 mg/kg/min), all of the
above responses to GGI were minimal with no statistical
significance compared to the basal levels at time 0 min
before glucose infusion, however, the GGI-induced re-
sponses were fully saturated at 32 mg/kg/min (Table 2).
Except for the increase in blood glucose concentration,
none of the other responses (insulin, C-peptide, C/I and
ISR) to GGI reached statistical significance at any time
points relative to the baseline values in the DM group.
Sensitivity of β-cell insulin secretion in response to
circulating glucose stimulation
The β-cell insulin secretory function in response to glu-
cose stimulation was also analyzed by the blood glucose
concentration-response curves for insulin, C-peptide,Dysmetabolic (DYS) Diabetic (DM)
8 (4/4) 4 (2/2)
16.0 ± 1.1* 16.1 ± 1.2*
9.0 ± 1.2 9.0 ± 1.8
68.5 ± 5.0* 171.5 ± 22.3*#
1.9 ± 0.2* 1.3 ± 0.1*#
0.38 ± 0.01* 0.43 ± 0.05*
21 ± 2.2* 23 ± 11*
with Fisher (LSD) post hoc comparisons.
Figure 1 Time course of the blood glucose (Top), serum concentrations of insulin (Second) and C-peptide (Third), molar ratio of C-peptide / insulin
(Fourth), and calculated insulin secretion rate (ISR) by deconvolution of serum C-peptide concentration decay curve (Fifth) induced by graded
glucose infusion (bottom) in the normal (N), dysmetabolic (DYS) and diabetic (DM) cynomolgus monkeys. Left: Basal level at the resting condition
before the graded glucose infusion.Middle: Time course during the graded glucose infusion. Right: Area under the curve (AUC) over the entire 200 min time
course. *Significantly different from normal group, # significantly different from dysmetabolic group, p<0.05, by ANOVA with Fisher (LSD) post hoc comparisons.
Table 2 The first time point (min) when the infusion of
glucose-induced responses reached a statistically
significant difference from the respective baseline values
at time 0 min measured by paired t test, p<0.05
(min) Normal DYS DM
Glucose 60 60 80
Insulin 40 100 NS
C-Peptide 40 100 NS
C/I 40 80 NS
ISR 20 75 NS
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were used to measure the sensitivity of β-cell in response
to the unit increment of blood glucose concentration
(Figure 2, right). The responses of all of the parameters,
including insulin, C-peptide and ISR, were highly and
positively correlated with the blood glucose concen-
trations (Figure 2, Left). The glucose concentration -
response curves for insulin and C-peptide were left-shifted
with a slight, but not significant increase in the slope in
the DYS, and dramatically right-shifted with a signifi-
cantly diminished slope in the DM, relative to the N
Figure 2 Blood glucose concentration-response curves (Left) for insulin (top), C-peptide (Second), molar ratio of C-peptide / insulin (Third),
insulin secretion rate (bottom) and the slopes of the concentration response curves (Right) in the normal (N), dysmetabolic (DYS) and diabetic
(DM) cynomolgus monkeys. *Significantly different from normal group, # significantly different from dysmetabolic group, p<0.05, by ANOVA with
Fisher (LSD) post hoc comparisons.
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ISR in the N and DYS groups did not differ from each
other, but this relationship was minimal in the DM
group, indicating that the β-cell insulin secretory re-
sponse to glucose stimulation was compromised in the
DM NHPs.
In contrast, the C/I response curves were negatively
correlated to the rising blood glucose concentrations in
all 3 groups, indicating that gradual elevation of glucose
concentration over the time course during the GGI was
associated with progressively reduced hepatic insulin ex-
traction, thus, considered an impairment of the MCRI.The curves between the N and DYS were close together,
but had a right shift in the DM group (Figure 2, left).
The slopes of glucose concentration - response for C/I
curves were similar between the N and DM, but signifi-
cantly lower in the DYS group (Figure 2, right), indicating
a higher level of saturation of the hepatic insulin extrac-
tion capacity probably due to the hyperinsulinemia.
Discussion
The present study examined the changes in β-cell insulin
secretory function during progressive stimulation by rises
in glucose levels with a GGI procedure in the cynomolgus
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to the normal monkeys, the DYS monkeys, under fasting
conditions, were characterized by a slight, but significant
hyperglycemia, accompanied by a marked hyperinsulinemia
and enhanced ISR with a lower systemic glucose clearance
and reduced hepatic MCRI. In contrast, the DM monkeys
had a marked hyperglycemia and a further diminished sys-
temic glucose clearance, but a higher hepatic MCRI. During
the GGI, there were significantly enhanced insulin and C-
peptide responses in the DYS compared to the N group,
which was dramatically depressed in the DM group. How-
ever, the GGI-induced increase in ISR was not significantly
different between N and DYS, although markedly dimin-
ished in the DM monkeys.
One hypothesis is that the pancreatic β-cells can main-
tain normal glucose homeostasis in the insulin-resistant
state during the prediabetic or dysmetabolic phase by a
compensatory increase in the β-cell response to glucose
stimulation [23]. Diabetes develops when there is deteri-
oration in β-cell insulin secretory responsiveness to glu-
cose due to β-cell failure [24]. Similar to dysmetabolic
humans, the DYS monkeys in the present study also
showed marked hyperinsulinemia, a characterization of
increased insulin resistance as defined by HOMA-IR or
decreased insulin insensitivity as defined by QUICKI.
Using the stepwise increment in glucose infusion rate to
gradually elevate blood glucose concentrations to stimu-
late β-cell insulin secretion, quantified as ISR, these DYS
monkeys were determined to have preserved β-cell insulin
secretory function, fully capable of increasing ISR to com-
pensate for the reduced tissue sensitivity to insulin, and
were thus, capable of maintaining glucose homeostasis.
In contrast, the DM monkeys’ β-cells were severely im-
paired, and incapable of increasing fasting as well as
GGI-stimulated ISR in the face of severe insulin resist-
ance, thus, leading to hyperglycemia. These data clearly
demonstrate that the β-cell function was enhanced in
the fasting state and maintained during the GGI in the
DYS, but significantly depressed in the DM monkeys.
These results are consistent with the reports in insulin-
resistant patients whose glucose homeostasis can be
maintained when the defect in insulin action is adequately
compensated for by an increase in insulin concentration.
While hyperinsulinemia has been generally attributed
to β-cell hypersecretion of insulin, it is not clear whether
it is a primary event governed either by central neural or
β-cell intrinsic regulation, or by a secondary event aris-
ing from an adaptive response to diminished peripheral
insulin sensitivity in the dysmetabolic state [25]. It has
been previously shown that non-diabetic insulin resist-
ant individuals have a left-shift of the glucose-stimulated
ISR dose–response curve when compared with normal
individuals; thus, at any given glucose concentration,
insulin-resistant individuals secrete more insulin thaninsulin-sensitive ones [26]. Furthermore, there is evidence
that the improvement in insulin sensitivity associated with
weight loss [10-13] or with 3 months of rosiglitazone
treatment [15] right-shifted the glucose-stimulated ISR
dose–response curve toward normal, leading to less
insulin secretion at any given glucose concentration.
Several factors have been hypothesized to contribute to the
progressive loss of β-cell function, including glucotoxicity
and lipotoxicity, amyloid accumulation, an increase in pro-
inflammatory cytokines, and increased secretory demand
because of peripheral insulin resistance [2,27]. The increase
in insulin requirement driven by insulin resistance may play
a contributory role in the deterioration of β-cell function
[27]. Therefore, interventions that help to preserve or im-
prove β-cell function and/or ameliorate insulin resistance
are likely to be effective in preventing or treating diabetes
[28]. Techniques to robustly quantify these improvements
in vivo in clinically relevant animal models are essential to
the evaluation of potential clinical efficacy in the discovery
and development of novel anti-diabetic therapeutics.
Blood insulin concentration is a dynamic balance be-
tween insulin production/secretion and clearance. In
addition to the changes in β-cell ISR, the MCRI is an-
other contributing factor to circulating insulin levels
[26,29]. Using the C/I ratio as an index of hepatic insu-
lin extraction rate or MCRI, the present data demon-
strate that the basal C/I was significantly lower, which
may also contribute to hyperinsulinemia in the DYS
cynomolgus monkeys. In contrast, the average C/I during
GGI calculated by AUC was significantly higher in the
DM group, which could contribute to the low circulating
insulin levels during the GGI. Indeed in insulin-resistant
individuals, MCRI has been shown to be decreased (26),
suggesting that changes in insulin resistance can inde-
pendently impact insulin clearance (15). The exact mech-
anism of such differences in hepatic insulin extraction rate
in different metabolic states is still unclear. The liver is a
major organ that clears insulin directly secreted from the
β-cells during the first pass through the portal circulation
with limited capacity. Previous studies have suggested that
hepatic insulin extraction rate may decline due to satur-
ation of hepatic insulin uptake at higher concentrations
[22]. Indeed, Hansen et al. reported that in dysmetabolic
rhesus monkeys, increasing portal insulin concentration
above 1,000 pM leads to a decrease of hepatic insulin ex-
traction by 40 to 60% [6]. This decline, therefore, contrib-
utes approximately 50% to the overall development of
hyperinsulinemia, the remainder of the increase being
related to β-cell hypersecretion of insulin. Using a double-
label method to measure MCRI and hepatic extraction
of exogenous insulin in conscious dogs, Pye et al. also
reported that as portal insulin levels were increased
from basal level to 3,738 pM, hepatic insulin uptake de-
creased from 61% to 29%, while the MCRI declined 3
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a saturation of hepatic insulin extraction occurs at ele-
vated insulin concentrations approaching 1,800 pM in
anesthetized dogs [31], 1,804 - 1,955 pM in dysmetabolic
rhesus monkeys [6], and 1,680 pM in men during exogen-
ous insulin infusion [32]. These levels are consistent with
the range of insulin concentrations in the present study
during GGI. Thus, the present data provide new evidence
in the cynomolgus monkey model of dysmetabolism
and diabetes that in addition to the β-cell insulin
hypersecretion, reduction in hepatic insulin clearance
possibly due to a saturation mechanism also contributes
to the development of hyperinsulinemia.
Concerning the GGI protocol itself, the present data
have shown that the effects at 2 mg/kg/min glucose in-
fusion rate were so minimal in all groups that this low
infusion rate can be eliminated as non-informative for
future studies of β-cell secretion/function. At the other
end of the infusion rates tested here, the highest rate of
32 mg/kg/min used in the present study produced extra-
ordinarily high glucose concentrations at non physio-
logical levels (often over 400 mg/dL) and saturated insulin
responses, which provided no additional information over
that provided by the 16 mg/kg/min infusion rate, indi-
cating that this high level can also be eliminated from
future GGI protocols. Thus, the most cost and effort
effective, and scientifically useful glucose infusion rates
for both humans and NHPs appear to be at the 8 and
16 mg/kg/min (40 min. each rate), as suggested in a
study by Ehrmann et al. and this allows ISR to be exam-
ined over glucose levels at a more physiological range
from 140–250 mg/dL in normal humans [14].
One limitation of the present study is the use of C-peptide
clearance parameters estimated from a human population
[8]. To date, C-peptide deconvolution approaches to
quantify β-cell function under stimulated conditions
have not been described in an NHP species. Direct
measurement of C-peptide kinetics individually in each
monkey would be laborious and time consuming. Al-
though there are other more sophisticated mathematical
models to analyze the glucose-insulin metabolism and
insulin sensitivity, in the present study, we adopted the
most simple methods and indices commonly used in the
literature.
Conclusion
The present data revealed that both an increased ISR
and reduced hepatic MCRI at the fasting stage con-
tribute to the hyperinsulinemia in the DYS monkeys.
However, there was no significant difference in glucose-
stimulated increase in ISR between the N and DYS
groups and a significantly reduced MCRI during GGI in
the DYS monkeys, indicating that the exaggerated eleva-
tion of insulin and C-peptide concentrations during GGIis predominantly contributed by a diminished hepatic
insulin clearance, probably a result of hyperinsulinemia-
induced saturation of the hepatic insulin extraction cap-
acity. In diabetic NHPs with impaired β-cell function,
the GGI-induced ISR was greatly depressed with a higher
MCRI, thus hyperglycemia developed. Therefore, the GGI
method combined with analysis of ISR by C-peptide de-
convolution in the NHP model of diabetes and metabolic
disorders provides a powerful translational tool for insight
into the trajectory of β-cell dysfunction in the develop-
ment of diabetes and for preclinical profiling of efficacy
of novel pharmaceutical agents targeting improvements
of β-cell function.Abbreviations
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